SMMT

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Retrieved on: 
Friday, March 22, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, SMMT, Intraparenchymal hemorrhage, Sun, EGFR, Central European Time, Metastasis, ELCC, Progression-free survival, Anaplastic lymphoma kinase, Constipation, Brain, Drug, HKEX, Safety, Anemia, Phase, Summit, TKI, Time in Europe, PFS, ALK, Pharmaceutical industry

The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.

Key Points: 
  • The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.
  • This analysis consisted of the 35 patients with advanced or metastatic NSCLC who had asymptomatic brain metastases at baseline; 28 patients were treated with ivonescimab plus chemotherapy in AK112-201, and seven patients were treated with monotherapy ivonescimab in AK112-202.
  • Patients across both cohorts experienced an intracranial response rate of 34%, and eight patients (23%) experienced a complete response by RANO criteria.
  • The most frequent TEAEs were anemia and decreased neutrophil counts in squamous patients and anemia and constipation in non-squamous patients.

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, SMMT, Sun, EGFR, Central European Time, ELCC, NSCLC, Anaplastic lymphoma kinase, Drug, HKEX, Safety, Phase, Summit, TKI, Time in Europe, ALK, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.
  • Two posters featuring updated ivonescimab data will be displayed on Friday, March 22 from 12:00 to 12:45pm Central European Time.
  • The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.
  • These patients were enrolled in either AK112-202 (NCT04900363), in which ivonescimab is delivered as monotherapy, or AK112-201 (NCT04736823), in which ivonescimab is delivered in combination with platinum doublet chemotherapy, both of which are Phase II clinical trials for patients with advanced or metastatic NSCLC.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT

Retrieved on: 
Thursday, March 7, 2024
LLP, News, Pomerantz, Sale, Summit, SMMT, Cryptocurrency

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).
  • The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On February 20, 2024, Summit reported its financial results for the fourth quarter and full year 2023 and “provide[d] an update on its operational progress”.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT

Retrieved on: 
Wednesday, February 28, 2024
Prior, LLP, News, Pomerantz, Sale, Summit, SMMT, Cryptocurrency

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).
  • The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On February 20, 2024, Summit reported its financial results for the fourth quarter and full year 2023 and “provide[d] an update on its operational progress”.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, March 5, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Barclays, SMMT, Conference

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26th Annual Global Healthcare Conference, which will be held in Miami Beach, FL, from March 12-14, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26th Annual Global Healthcare Conference, which will be held in Miami Beach, FL, from March 12-14, 2024.
  • Dr. Maky Zanganeh, Chief Executive Officer and President, and Robert W. Duggan, Chairman and Chief Executive Officer, will present on behalf of our organization and provide details regarding the development of our innovative investigational bispecific antibody, ivonescimab, on Tuesday March 12, 2024 at 2:35pm ET.
  • They will be joined by Manmeet Soni, Chief Operating Officer; Dave Gancarz, Chief Business & Strategy Officer; and Dr. Allen S. Yang, Chief Medical Officer.
  • An archived version will be available on our website following the presentation.

Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Retrieved on: 
Monday, February 26, 2024
Class Action Lawsuit, Professional Services, Legal, News, Sale, Summit, SMMT

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Summit Therapeutics Inc. (“Summit” or “the Company”) (NASDAQ: SMMT).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Summit Therapeutics Inc. (“Summit” or “the Company”) (NASDAQ: SMMT).
  • Investors who purchased Summit securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SMMT .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023

Retrieved on: 
Tuesday, February 20, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, NSCLC, Paranal Observatory, Cohort, EGFR, Research, Neoplasm, Forecasting, Immunotherapy, ASCO, Investment, FDA, SITC, Table, PD-1, SMMT, Society, Annual general meeting, IPR, Lung cancer, GAAP, VEGF, The Wall Street Journal, Tumor microenvironment, Webcast, Patient, Phase, Trial of the century, Summit, TKI, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the fourth quarter and year-ended December 31, 2023.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the fourth quarter and year-ended December 31, 2023.
  • Summit received the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan.
  • In exchange for these rights, Summit made an upfront payment of $500 million in 2023.
  • Non-GAAP R&D expenses were $22.4 million for the fourth quarter of 2023, as compared to $4.4 million for the same period of the year period.

Summit Therapeutics to Host Fourth Quarter & Full Year 2023

Retrieved on: 
Wednesday, February 14, 2024
Research, Public Relations, Investor Relations, Clinical Trials, Communications, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Summit, SMMT

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2023 financial results and provide an operational update for the Company on Tuesday, February 20, 2024, before the market opens.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2023 financial results and provide an operational update for the Company on Tuesday, February 20, 2024, before the market opens.
  • Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website www.smmttx.com .
  • An archived edition of the session will be available on our website.

Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Wednesday, February 7, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SMMT, Conference

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference, which will be held virtually.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference, which will be held virtually.
  • Summit will present on Wednesday, February 14, 2024, at 2:40PM ET.
  • Dr. Maky Zanganeh, Chief Executive Officer and President, and Robert W. Duggan, Chairman and Chief Executive Officer, will present on behalf of our organization and provide details regarding the development of our innovative investigational bispecific antibody, ivonescimab.
  • An archived version will be available on our website following the presentation.

SMMT - UK Auto makes one million vehicles and welcomes £23.7 billion investment boost

Retrieved on: 
Thursday, January 25, 2024
EVS, BEV, JLR, RRP, Heart, HEV, Policy, Climate change, Society, Education minister, Government, Tata, Growth, Investment, Red, EV, SMMT, CVS, PHEV, Renewable energy

LONDON, Jan. 25, 2024 /PRNewswire/ -- UK vehicle production hit 1,025,474 units in 2023, according to the latest figures published today by the Society of Motor Manufacturers and Traders (SMMT). With 905,117 cars and 120,357 commercial vehicles (CVs) produced, output was up 17.0% on the previous year. The easing of pandemic-related challenges, from chip shortages to lockdowns, and increasing electrified model production, combined to drive annual output above one million for the first time since 2019.[1]

Key Points: 
  • LONDON, Jan. 25, 2024 /PRNewswire/ -- UK vehicle production hit 1,025,474 units in 2023, according to the latest figures published today by the Society of Motor Manufacturers and Traders (SMMT).
  • With 905,117 cars and 120,357 commercial vehicles (CVs) produced, output was up 17.0% on the previous year.
  • Mike Hawes, SMMT Chief Executive, said, "Receding supply chain challenges, new model introductions and a massive £23.7 billion of investment put UK vehicle production firmly back on track in 2023.
  • [3]: SMMT calculations based on publicly announced investment commitments, public and private, in UK automotive production and R&D 2023 from brands including but not limited to: MINI, JLR, Tata and Nissan.